DV
Dividend Vision

IMVT — Immunovant, Inc.

Immunovant, Inc. (IMVT)

Total return is 320.3% over the past 7.1 years, 127.8 points ahead of SPY at 192.5%. Its deepest 1-year drawdown was 17.2%.

IMVT is a single-stock equity holding in Immunovant, Inc., a biopharmaceutical company focused on autoimmune disease treatments. As a stock rather than a diversified ETF, it does not have a traditional dividend distribution rate or expense ratio, and it carries concentrated company-specific risk. This holding appeals primarily to investors seeking targeted exposure to the biotechnology sector rather than those pursuing passive dividend income.

IMVT key facts

Asset type
Stock
Asset class
Equity
Inception date
06/21/2019
Distribution frequency
None
Last close
$41.82
Market cap
$8,638,032,896
Average volume
722489.0
Beta
0.81
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.81